General Info

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The company has collaborated with pharmaceutical partners to develop and market product candidates. Rigel has product development programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis, thrombocytopenia, asthma and allergy, as well as in cancer. Its lead product candidate, R788, completed Phase I clinical trials for the treatment of rheumatoid arthritis, in 2005.